Daily Archives: September 8, 2020

RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2

Opaganib blocks SARS-Cov-2 virus replication

Opaganib blocks SARS-Cov-2 virus replication

Opaganib completely inhibited SARS-CoV-2 viral replication as measured after three days incubation in an in vitro model of human bronchial tissue, comparing favorably with remdesivir, the positive control in the study

Opaganib is uniquely positioned as an orally-administered potential COVID-19 treatment combining potent antiviral and anti-inflammatory mechanisms of action, targeting a host cell component and minimizing likelihood of resistance

Global Phase 2/3 and U.S. Phase 2 clinical studies ongoing with opaganib for severe COVID-19 pneumonia

RedHill’s second COVID-19 drug candidate, RHB-107 (upamostat), a novel serine protease inhibitor, strongly inhibited SARS-CoV-2 viral replication in the same model, further supporting planned initiation of a Phase 2/3 U.S. outpatient study later this year

       

TEL AVIV, Israel and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that opaganib1 demonstrated potent inhibition of SARS-CoV-2, the virus that causes COVID-19, achieving complete blockage of viral replication in an in vitro model of human lung bronchial tissue. Opaganib is a first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with dual anti-inflammatory and anti-viral activity that targets a host cell component, unaffected by viral mutation, thus minimizing the likelihood of resistance. Opaganib is currently being evaluated in global Phase 2/3 and U.S. Phase 2 clinical studies for the treatment of severe COVID-19 pneumonia.

Working in collaboration with the University of Louisville Center for Predictive Medicine, opaganib was studied in a 3D tissue model of human bronchial epithelial cells (EpiAirway) which morphologically and functionally resembles the human airway and is similar to the model used to discover SARS-CoV-22. This study was designed to evaluate the in vitro efficacy of opaganib in inhibiting SARS-CoV-2 infection and included a positive control of remdesivir, a drug with known antiviral activity.

Results from this study showed a clear and compelling antiviral effect of opaganib against SARS-CoV-2. Opaganib demonstrated the most potent activity compared to all compounds tested, including the positive control, remdesivir. Treatment of cells infected with SARS-CoV-2 resulted in a dose-dependent inhibition of virus production without compromising cell membrane integrity, a measure of cell viability and drug safety, further demonstrating opaganib’s promising potential for treating patients with COVID-19.

A graphic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e60ced55-ca9d-4648-81cb-907be7571136

Opaganib at 1mg/ml (a pharmacologically relevant concentration) completely inhibited viral replication as measured after three days of incubation. This potent opaganib activity compares favorably with remdesivir data as the active control in the RedHill study which is consistent with published remdesivir data3.  Data from the study is planned to be submitted to a peer-reviewed journal.

“Opaganib’s previously demonstrated anti-inflammatory activity, combined with our now proven specific anti-SARS-CoV-2 viral activity, provides a unique dual mechanism of action with the potential to greatly benefit COVID-19 patients by inhibiting the key drivers of disease progression – viral replication and lung inflammation,” said Mark L. Levitt, M.D., Ph.D., Medical Director at RedHill. “These compelling data, using a physiologically relevant human respiratory tissue model, demonstrate opaganib’s potential to strongly inhibit SARS-CoV-2 viral replication, validating the hypotheses underlying our ongoing global Phase 2/3 and U.S. Phase 2 clinical studies and further supporting their rationale. Accordingly, we are accelerating progress toward our goal of generating a robust data package to potentially support emergency use authorizations for COVID-19.”

The ongoing global multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 study (NCT04467840) evaluating opaganib for the treatment of patients with severe COVID-19 pneumonia continues to enroll with a target of up to 270 patients requiring hospitalization and treatment with supplemental oxygen. The study recently received approval in Israel and has been approved in the United Kingdom, Italy, Russia and Mexico, with further expansion progressing.

In parallel, the randomized, double-blind, placebo-controlled U.S. Phase 2 study (NCT04414618) with opaganib in patients with severe COVID-19 pneumonia is more than 50% enrolled, with enrollment set to be completed in the coming weeks. Recently, a pre-scheduled independent Safety Monitoring Committee recommended that the study continue without change. The study, which is not powered for statistical significance, is set to enroll up to 40 patients requiring hospitalization and supplemental oxygen.

The Company is in discussions with U.S. government agencies around potential funding to support the rapid advancement of opaganib toward potential emergency use approval.

In addition to opaganib, RedHill’s in-vitro study evaluated the antiviral activity of its Phase-2 stage investigational drug, RHB-107 (upamostat), a serine protease inhibitor active against a number of human serine proteases, with results demonstrating potent inhibition of SARS-CoV-2 viral replication. A U.S. Phase 2/3 study with RHB-107 in an outpatient setting is planned to be initiated later this year.

“Host cellular proteases play a critical role in the process of SARS-CoV-2 entry into cells, specifically responsible for activating the SARS-CoV-2 spike (S) protein, which is a prerequisite for the fusion of viral and host cell membranes during viral entry,” said Terry F. Plasse MD, Medical Director at RedHill. “RHB-107 demonstrated excellent antiviral activity, with viral replication being strongly inhibited in a dose-dependent manner at pharmacologically relevant concentrations. As with opaganib, RHB-107 (upamostat) is orally bioavailable and therefore potentially suitable for both inpatient and out-patient settings.”

The results from the preclinical studies of opaganib and RHB-107 are preliminary and were provided to the Company by an independent third-party following an initial independent analysis and remain subject to additional review and analysis of the data and potentially supportive experiments.

About Opaganib (ABC294640, Yeliva®)
Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with anticancer, anti-inflammatory, and antiviral activities, targeting multiple oncology, viral, inflammatory, and gastrointestinal indications.

Opaganib received Orphan Drug designation from the U.S. FDA for the treatment of cholangiocarcinoma and is being evaluated in a Phase 2a study in advanced cholangiocarcinoma and in a Phase 2 study in prostate cancer. Opaganib is also being evaluated in a global Phase 2/3 study and a U.S. Phase 2 study for the treatment of coronavirus (COVID-19).

Preclinical data have demonstrated both anti-inflammatory and antiviral activities of opaganib, with the potential to reduce lung inflammatory disorders, such as pneumonia, and mitigate pulmonary fibrotic damage. Opaganib demonstrated potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19, completely inhibiting viral replication in an in vitro model of human lung bronchial tissue. Additionally, preclinical in vivo studies4 have demonstrated that opaganib decreased fatality rates from influenza virus infection and ameliorated Pseudomonas aeruginosa-induced lung injury by reducing the levels of IL-6 and TNF-alpha in bronchoalveolar lavage fluids.

Opaganib was originally developed by U.S.-based Apogee Biotechnology Corp. and completed multiple successful preclinical studies in oncology, inflammation, GI, and radioprotection models, as well as a Phase 1 clinical study in cancer patients with advanced solid tumors and an additional Phase 1 study in multiple myeloma.

Under a compassionate use program, COVID-19 patients (as classified by the WHO ordinal scale) were treated with opaganib in a leading hospital in Israel. Data from the treatment of these first patients with severe COVID-19 with opaganib have been published2. Analysis of treatment outcomes suggested substantial benefit to patients treated with opaganib under compassionate use in both clinical outcomes and inflammatory markers as compared to a retrospective matched case-control group from the same hospital. All patients in the opaganib-treated group were discharged from hospital without requiring mechanical ventilation, whereas 33% of the matched case-control group required mechanical ventilation. Median time to weaning from high-flow nasal cannula was reduced to 10 days in the opaganib-treated group, as compared to 15 days in the matched case-control group.

The development of opaganib has been supported by grants and contracts from U.S. federal and state government agencies awarded to Apogee Biotechnology Corp., including from the NCI, BARDA, the U.S. Department of Defense and the FDA Office of Orphan Products Development.

The ongoing studies with opaganib are registered on www.ClinicalTrials.gov, a web-based service by the U.S. National Institute of Health, which provides public access to information on publicly and privately supported clinical studies.

About RHB-107 (upamostat)
RHB-107 is a proprietary, first-in-class, orally-administered potent inhibitor of several serine proteases, with demonstrated antiviral and potential tissue-protective effects. This combined antiviral and potential tissue-protective action make it a strong candidate for evaluation as a treatment for COVID-19 infection. In addition, RHB-107 has potential in targeting cancer, inflammatory lung diseases and gastrointestinal diseases, and has undergone several Phase 1 studies and two Phase 2 studies, demonstrating its clinical safety profile in over 300 patients. RedHill acquired the exclusive worldwide rights to RHB-107, excluding China, Hong Kong, Taiwan and Macao, from Germany’s Heidelberg Pharmaceuticals (formerly WILEX AG) for all indications.

About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults5, Talicia®for the treatment of Helicobacter pylori (H. pylori) infection in adults6, and Aemcolo® for the treatment of travelers’ diarrhea in adults7. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (ii) opaganib (Yeliva®), a firstinclass SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (iv) RHB-102 (Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v) RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases and is also being evaluated for COVID-19 and (vi) RHB106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com.

The results from the preclinical studies of opaganib and RHB-107 are preliminary and were provided to the Company by an independent third party following an initial independent analysis and remain subject to additional review and analysis of the data and potentially supportive experiments. Such review and analysis may result in findings inconsistent with the results disclosed in this release and may not be replicated in future pre-clinical or clinical trials.  Accordingly,  investors should not rely on the results described in this release as definitive proof of the antiviral effect of opaganib against SARS-CoV-2 and whether in fact opaganib will be an effective treatment of SARS-CoV-2.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the risk that the Company’s Phase 2/3 study evaluating RHB-107 will not be successful, if conducted at all; the risk the antiviral activity in the in vitro study will not be demonstrated in clinical trials; the risk of a delay in receiving data to support applying for emergency use applications; the risk that the U.S. Phase 2 clinical study evaluating opaganib will not be successful and the risk that completion of enrollment for this clinical study will be delayed; the risk that the Company will not initiate the Phase 2/3 study for opaganib in certain geographies, will not expand this study in additional countries and that it will not be successful; the risk that the Company will not initiate the Phase 2/3 study in COVID-19 with RHB-107 or that it will be delayed;  the risk that other COVID-19 patients treated with opaganib will not show any clinical improvement; the risk that clinical trials with opaganib in Israel, the U.S., Italy, Russia, the UK, Mexico or elsewhere for the treatment of COVID-19, if conducted at all, will not show any improvement in patients; the risk of a delay in applying for emergency use authorizations; the development risks of early-stage discovery efforts for a disease that is still little understood, including difficulty in assessing the efficacy of opaganib for the treatment of COVID-19, if at all; intense competition from other companies developing potential treatments and vaccines for COVID-19; the effect of a potential occurrence of patients suffering serious adverse events using opaganib under compassionate use programs, as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of Mycobacterium avium subspecies paratuberculosis (MAP); (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates and Talicia®; (v) the Company’s ability to successfully commercialize and promote Movantik®, Talicia® and Aemcolo®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build and sustain its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and commercial products and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse events using investigative drugs under the Company’s Expanded Access Program; and (xiv) competition from other companies and technologies within the Company’s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on March 4, 2020. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

Company contact:
Adi Frish
Senior VP Business Development & Licensing
RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com
IR contact (U.S.):
Timothy McCarthy, CFA, MBA
Managing Director, Relationship Manager
LifeSci Advisors, LLC
+1-212-915-2564
tim@lifesciadvisors.com

 

________________________________
1 Opaganib (Yeliva®, ABC294640) is an investigational new drug, not available for commercial distribution.
2 Na Zhu et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-33.
3 Pruijssers AJ et al. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Reports. Vol 32, Issue 3, 107940, July 21, 2020.
4 Xia C. et al. Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice. Antiviral Res. 2018 Oct; 158:171-177. Ebenezer DL et al. Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. Thorax. 2019 Jun;74(6):579-591.
5 Full prescribing information for Movantik® (naloxegol) is available at: www.Movantik.com.
6 Full prescribing information for Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is available at: www.Talicia.com.
7 Full prescribing information for Aemcolo® (rifamycin) is available at: www.Aemcolo.com.

Quad Channel High Current Linear LED Controller for Automotive Exterior Lighting Applications

Drive 1A LEDs for Tail /Stop Rear Combination Lamps and Daytime Running Lamps with integrated PWM

Quad Channel High Current Linear LED Controller for Automotive Exterior Lighting Applications

The IS32LT3123 is an AEC-Q100 controller which integrates a programmable PWM dimming engine to achieve two brightness levels for the “Tail” (PWM dimming) and “Stop” (full brightness) intensities in RCL applications or day/night intensities for DRL applications.

MILPITAS, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) — Lumissil Microsystems, a division of ISSI, today announced the release of a 4-channel linear current controller for automotive RCL (Rear Combination Lamp), DRL (Daytime Running Lamp) and “Welcome” LED lighting applications.  The IS32LT3123 is an AEC-Q100 controller which integrates a programmable PWM dimming engine to achieve two brightness levels for the “Tail” (PWM dimming) and “Stop” (full brightness) intensities in RCL applications or day/night intensities for DRL applications.  It controls four external MOSFETs for extended reliability at high currents with optimum thermal dissipation of each LED channel.

The controller provides engineers with flexibility in the design of dual intensity lights tuned to the lamp’s optical and thermal constraints.  The integrated PWM engine’s duty cycle and operating frequency can be programmed with external resistors while a single-pin selects between full brightness and PWM dimming levels. Selecting and sizing the external MOSFETs along with their associated sense resistors add current-level tuning flexibility for each of the four channels while spreading out the resulting thermal heat.

“Automotive lighting engineers using the IS32LT3123 will find that it fully addresses their design concerns with high current, thermal dissipation, dimming control, and system EMI,” said Ven Shan, VP of Marketing at Lumissil Microsystems.  “The advanced features of the IS32LT3123 controller will provide designers with the ease and flexibility to quickly realize their automotive lighting applications over a wide power level.”

Multiple IS32LT3123 controllers can be linked together, all sharing a common PWM timing reference generated from a single controller or from an external source.  Furthermore, the controller’s four PWM outputs have adjustable slew rate control for optimized EMI performance. For robust system reliability, the IS32LT3123 integrates fault detection and reporting circuit for LED open and short circuit, input over voltage and over temperature conditions.

The IS32LT3123 addresses thermal issues by providing a control interface for external MOSFETs which sustain the bulk of the thermal dissipation.  For added thermal reliability, the controller also enables thermal management of the LED strings themselves.  An external NTC thermistor placed close to the LEDs and monitored by the IS32LT3123 will provide an adjustable current roll off to protect the LEDs should they reach a predefined thermal stress level.

Availability, Packaging and Pricing

The IS32LT3123-ZLA3-TR is an AEC-Q100 qualified controller, comes in an eTSSOP-24 package and operates from a 5.0V to 40V voltage supply.  The IS32LT3123 is sampling and is available for production with pricing beginning at $0.75 for quantities of 10K pcs.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c1b6dc41-dd79-4cfb-9f2c-afa9677bccc1

About Lumissil

Lumissil is the analog/mixed-signal product division of ISSI, a fabless semiconductor company that designs and markets high performance integrated circuits for the following key markets: (I) automotive, (ii) communications, (iii) industrial/medical, and (iv) digital consumer. Lumissil’s primary products are LED drivers for low to mid-power RGB color mixing and high power lighting applications. Other products include audio, sensor, high speed wired communications, optical networking ICs and Application-specific microcontrollers. ISSI/Lumissil is headquartered in Silicon Valley with worldwide offices in Taiwan, Japan, Singapore, China, Europe, Hong Kong, India, and Korea.  Visit our web site at http://www.lumissil.com/

About Integrated Silicon Solution, Inc. (ISSI)

ISSI is a fabless semiconductor company that designs, develops and markets high performance SRAM, DRAM, Flash memory (including NOR flash, NAND flash and managed NAND solutions (eMMC)), and Analog/Mixed-signal integrated circuits. ISSI provides high-quality semiconductor products and has been a committed long-term supplier to its customers.  ISSI is headquartered in Silicon Valley with worldwide offices in Taiwan, Japan, Singapore, China, Europe, Hong Kong, India, and Korea. Visit our web site at http://www.issi.com/

Integrated Silicon Solution, Inc.
Ven Shan
408 969 4622
vshan@lumissil.com

Aaron Reynoso
408 969 5141
areynoso@lumissil.com

Philips’ Future Health Index 2020 report reveals new insights into younger doctors’ commitment to improving healthcare during COVID-19

September 8, 2020

  • 61% of younger doctors ranked telehealth as the digital health technology that would have most improved their experiences during COVID-19, overtaking artificial intelligence (AI) (53%)
  • 47% of younger doctors reported greater appreciation from patients; 44% experienced greater collaboration with colleagues across different skill sets
  • Only 9% of younger doctors surveyed are more likely to leave medicine as a result of their experiences during COVID-19, while over one third (38%) are more likely to stay

Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the results of its latest piece of Future Health Index (FHI) 2020 research. The Future Health Index Insights: COVID-19 and Younger Healthcare Professionals survey supplements the main FHI 2020 report, capturing feedback from 500 doctors under the age of 40 in five countries: the United States of America, China, Singapore, France and Germany. The findings reveal how the COVID-19 pandemic has affected the attitudes and experiences of younger doctors, and how they believe the healthcare industry should change in response.

“Healthcare professionals, including the younger generation, have experienced unprecedented levels of stress and were often faced with limited resources in recent months. We must acknowledge the heroic sacrifices that frontline healthcare professionals have endured in the fight against COVID-19. We owe it to them to listen to their voices as we consider the future of the healthcare industry,” said Jan Kimpen, Chief Medical Officer, Royal Philips. “Our FHI Insights survey reveals that despite the challenges they’ve faced, younger doctors are as committed as ever to their vocation. The research spotlights how young doctors perceive change, and is relevant to leaders focused on reshaping how healthcare is being organized and delivered.”

Telehealth overtakes AI in the eyes of younger doctors
The COVID-19 pandemic has prompted younger doctors to change their attitudes to the relative benefits of different health technologies. It has led to a shift in priorities, with younger doctors recognizing the immediate value of telehealth. Before the pandemic, 60% of younger healthcare professionals ranked AI as the top digital health technology that would most improve their work satisfaction, with 39% identifying telehealth as the top technology. 61% of younger doctors now rank telehealth as the digital health technology that would have most improved their experiences at this time, with AI falling to 53%.

Younger doctors surveyed believed that there is room for improvement in how these technologies are used in everyday practice. When asked what would have helped them leverage the health data available to them during the height of the pandemic, nearly half (47%) of younger doctors pointed to better integration of healthcare data between hospitals/practices and between different IT systems or electronic medical records.

Younger doctors want more digital technology
For many younger doctors, working through COVID-19 has shown what a more technologically forward-thinking workplace could look like, with 44% reporting the pandemic exposed them to new ways of using digital health technologies.

As the healthcare sector prepares for the future, many younger doctors hope these advancements will become permanent fixtures of their post-COVID-19 workplace environments. When asked what changes in healthcare they most hoped would become outlast the pandemic, younger doctors ranked exposure to new types of digital health technologies (29%), new ways to use digital health technologies (29%), greater appreciation from patients (29%), and accelerated availability of digital health technologies (28%) as their top responses.

Many younger doctors are more committed than ever to their careers
The pandemic is presenting healthcare professionals with even greater workplace hardships and moral dilemmas, which are very likely to exacerbate existing levels of burnout and related mental health problems [1]. However, according to the FHI 2020 Insights survey, many younger doctors (38%) say they are more likely to stay in medicine as a result of their experiences working during COVID-19. Most (53%) said COVID-19 had no effect on them wanting to stay in or leave the profession, and only 9% said they were more likely to leave the profession.

Many younger doctors also reported changes in their day-to-day work during the pandemic, which could lead to increased career and personal satisfaction. 47% reported greater appreciation from patients, while 44% experienced greater collaboration with colleagues across different skill sets. Younger doctors in China stood out by reporting a deeper feeling of purpose at work (70%) since the onset of COVID-19.

Since 2016, Philips has conducted original research to help determine the readiness of countries to address global health challenges and build efficient and effective healthcare systems. For details on the Future Health Index methodology and to access the 2020 report in its entirety, including the FHI Insights: COVID-19 and Young Healthcare Professionals research, visit the Future Health Index site.

[1] National Academy of Medicine: https://nam.edu/initiatives/clinician-resilience-and-well-being/clinician-well-being-resources-during-covid-19/

Research methodology
The Future Health Index Insights: COVID-19 and Younger Healthcare Professionals survey was fielded from June 19 to July 30, 2020 in 5 countries (China, France, Germany, Singapore and the United States of America) in their native language. The survey was conducted online and offline (as relevant to the needs of each country) with a sample size of 100 per country for doctors under 40 years old, who have completed their first medical degree. The survey length was approximately 10 minutes. The total sample from the survey includes 500 doctors under 40 years old.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel. : +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly

Joost Maltha
Philips Global Press Office
Tel. : +31 6 10 55 8116
E-mail : joost.maltha@philips.com
Twitter: @joostmaltha

About Royal Philips 
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

Teledyne e2v’s new optical module ideal for scanning, embedded imaging and IoT applications

New 2MP Global Shutter MIPI module will enhance productivity and throughput

Teledyne e2v’s new 2MP optical module

New 2MP optical module offers reduced development time and cost savings

GRENOBLE, France, Sept. 08, 2020 (GLOBE NEWSWIRE) — Teledyne e2v, a Teledyne Technologies [NYSE: TDY] company and global innovator of imaging solutions, announces that it has expanded its product portfolio with a 2 Megapixel compact module featuring a pre-focused, industrial-grade scanning optic. This MIPI interfaced module finds a variety of uses in scanning, embedded vision and many other computer vision applications to enhance productivity and throughput in logistics, sorting, retail POS, and many other industrial sectors.

The 2MP optical module includes our small, state-of-the-art Snappy 2MP CMOS sensor which features a 2.8 µm low-noise global shutter pixel. Designed specifically for scanning and embedded vision applications, the sensor includes our patented Fast Self-Exposure™ mode that ensures the first, and all subsequent frames, are correctly exposed, this enables the fastest possible decoding/image processing by the downstream digital system, even in rapidly changing light conditions. The module has a 20 mm x 20 mm x 16 mm mechanical outline and is fitted with a custom-designed, high depth of field, high quality lens for applications that typically require a greater working range. Semi-customization is possible when alternative optical specifications are required.

As a turnkey sensor/optics for imaging systems, this 2MP module offers customers significant reduction in development time and cost savings. Only a few screws are needed to mount the module, with simple connection to the image processing system through an FPC cable connector. Software development efforts can also be reduced by using some limited API-layer Linux software drivers. This enables the module to be seamlessly interfaced to popular ISP platforms.

Gareth Powell, Senior Marketing Manager at Teledyne e2v, said, “This 2MP optical module is an exciting launch and the fore-runner in a family of MIPI modules. It provides customers with a solution to significantly reduce their integration times and shorten their time to market.”

Datasheets, user-guides, evaluation kits and samples are now available.

Please visit the product page or contact us for more information.

For media enquiries, please contact:
Jessica.Broom@teledyne.com | + 44 (0)1245 453607

Notes to Editors:
Teledyne e2v is part of the Teledyne Imaging Group. Their innovations lead developments in healthcare, life sciences, space, transportation, defence and security and industrial markets. Teledyne e2v’s unique approach involves listening to the market and application challenges of customers and partnering with them to provide innovative standard, semi-custom or fully-custom imaging solutions, bringing increased value to their systems.

For more information, visit imaging.teledyne-e2v.com

Teledyne Imaging is a group of leading-edge companies aligned under the Teledyne umbrella. Teledyne Imaging forms an unrivalled collective of expertise across the spectrum with decades of experience. Individually, each company offers best-in-class solutions. Together, they combine and leverage each other’s strengths to provide the deepest, widest imaging and related technology portfolio in the world. From aerospace through industrial inspection, scientific research, spectroscopy, radiography and radiotherapy, geospatial surveying, and advanced MEMS and semiconductor solutions, Teledyne Imaging offers world-wide customer support and the technical expertise to handle the toughest tasks. Their tools, technologies, and vision solutions are built to deliver to their customers a unique and competitive advantage.

For more information, visit www.teledyneimaging.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7fb84f34-4d5d-4940-acd4-4b040a4f8a31